Actively Recruiting
Evaluating the Effectiveness of 2LHERP4 Compared to Placebo in Adults With Recurrent Orofacial Herpes Infections
Led by Labo'Life · Updated on 2026-08-27
140
Participants Needed
6
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Herpes simplex virus HSV infection is very common and usually causes sores that can appear at any age. There is currently no antiviral treatment that completely cures or eradicates the virus. This clinical trial is designed to evaluate the effectiveness of 2LHERP4, an immune regulator used in treating herpetic infections, in reducing the recurrence of orofacial herpes infections in adults. Participants will be randomly assigned to receive either 2LHERP4 or a placebo for 6 months. The treatment involves taking one capsule daily before breakfast on an empty stomach, following a sequential order from capsule 1 to 10 and then repeating. After the treatment phase, there will be a 6-month follow-up period to assess the long-term effects of the treatment. During the study, participants will be monitored for the number and duration of herpes episodes, time to first recurrence, symptom severity including pain, use of rescue medication, quality of life, and safety. Data will be collected through patient diaries, questionnaires, and clinical assessments over a total duration of 12 months after treatment initiation to evaluate the efficacy and safety of 2LHERP4 compared to placebo.
CONDITIONS
Brief Title
Randomized, Placebo-controlled, Double-blind Study of 2LHERP® in Orofacial Herpes Infections.
Research Team
L
Laura FERTE
C
Charlotte BOLLE
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here